canadian generic market
DESCRIPTION
Canadian generic market potentialityTRANSCRIPT
1
Overview of Canadian Generic Prescription Drug Market
12 months ending September 2007
2
12 months ending September 2007
Brand
Generic
$18.7 billion
Brand
Generic
435 million Rx's
47.6%19.8%
80.2% 52.4%
The Canadian Prescription Drug Market
Source:
3
1.882
2.109
2.499
2.852
3.254
3.697
0
0.5
1
1.5
2
2.5
3
3.5
4
$ b
illio
n
2002 2003 2004 2005 2006 MAT 09/07
Canadian Generic Prescription Drugstore & Hospital Market
Source:
4
Generic Share of the
Canadian Prescription Drug Market
40.041.6
43.845.2
47.6
15.016.2 17.3 18.2
19.8
39.6
14.6
5
10
15
20
25
30
35
40
45
50
2002 2003 2004 2005 2006 MAT 09/07
$%
RX's $'s
Source:
5
The Canadian Prescription Drug Market
12.9314.08
15.4216.52
17.8518.66
2.11 2.50 2.853.25 3.70
1.88
0
4
8
12
16
20
2002 2003 2004 2005 2006 MAT 09/07
$ billions
Total Generic
Source:
6
GrowthBrand vs. Generic Drugstore & Hospital Sales
8.9 8.4
12.1
9.6
8.0
18.5
7.1
5.7
14.2
8.16.8
14.1
6.4
4.2
16.4
0
5
10
15
20
2003 2004 2005 2006 MAT 09/07
Total Brand Generic
Source:
7
Regional Market Share of Generic Sales
24.3%
22.7%
19.5% 15.7%
Canada: 19.8%
N.B. 24.7%N.S. 24.3%PEI & 24.8%Nfld.
20.9%24.4%
Source: IMS D&H Regional
NunavutNorthwest Territories
Yukon Territory
12 months ending September 2007
8
Generic Rx Penetration by RegionGeneric Rx Penetration by Region
54.6%56.7%
50.7%52.0% 49.3%
51.3%
42.2%43.0%
Canada:MAT 09/07 47.6%QTR3 /07 49.1%
N.B. 54.2% 56.4%N.S. 50.1% 51.9%PEI & 51.1% 53.3%Nfld.
49.6%51.5%
54.2%54.8%
Source: IMS Compuscript
NunavutNorthwest Territories
Yukon Territory
9
Generic Rx Penetration by Region
Source:
Atlantic Quebec Ontario Prairies Manitoba Sask. AlbertaBritish
Columbia CANADA
2002 43.1 35.2 40.8 42.5 43.3 45.7 41.0 45.5 39.6
2003 44.0 36.2 40.4 42.5 43.4 45.7 41.0 45.7 40.0
2004 46.1 37.4 42.2 44.7 46.4 46.3 43.3 48.2 41.6
2005 47.8 39.9 44.5 46.5 48.9 47.4 45.2 49.9 43.8
2006 49.1 41.1 45.9 48.2 51.3 48.0 47.0 51.2 45.2
MAT 09/07 51.7 42.2 49.3 50.9 54.2 50.7 49.6 54.6 47.6
10
Ranking of Drugstore & Hospital Sales by Corporation
Source:
2002 2003 2004 2005 2006MAT 09/07 Corporation $(million)
Market Share Growth
Total Market 18,662 6.41 1 1 1 1 1 Pfizer 2,286 12.2 8.36 6 5 5 3 2 Apotex Inc. 1,229 6.6 14.65 4 3 3 4 3 J&J 1,211 6.5 -5.54 3 2 2 2 4 Astra Zeneca 1,187 6.4 1.52 2 4 4 5 5 Glaxo SmithKline 1,011 5.4 3.07 7 7 7 7 6 Novartis 682 3.7 5.5
13 12 10 10 9 7 Lilly 647 3.5 5.99 11 12 13 12 8 Abbott 641 3.4 17.9
16 17 16 14 14 9 Novopharm 634 3.4 30.515 15 14 12 10 10 Roche 608 3.3 5.03 5 6 8 13 11 Merck Frosst 572 3.1 9.7
10 9 11 11 11 12 Bristol-Myers Squibb 560 3.0 3.48 8 8 6 6 13 Sanofi-Aventis 537 2.9 -19.3
12 13 13 15 15 14 Bayer 511 2.7 13.311 10 9 9 8 15 Wyeth 490 2.6 -22.914 14 15 16 16 16 Schering-Plough 488 2.6 13.427 22 21 19 17 17 Amgen 426 2.3 19.718 18 18 17 19 18 ratiopharm 403 2.1 10.0
Rank MAT 09/07
11
Leading Products by Drugstore & Hospital Sales 12 months ending September 2007
Source:
Top 15 products represent 22% of total ($’s) market
Chemical Product
Brand Launch
Date CorporationSales
$(000's) Growth
Share of Corp.'s Revenue
atorvastatin Lipitor Mar-97 Pfizer 1,094,897 9.2 47.9amlodipine Norvasc Sep-92 Pfizer 410,960 11.5 18.0pantoprazole sodium Pantoloc Mar-97 Nycomed Canada 318,457 13.5 94.9rosuvastatin Crestor Feb-03 AstraZeneca 269,982 43.5 22.7clopidogrel bisulfate Plavix Oct-98 Bristol-Myers Squibb 218,439 5.1 39.0ramipril Altace Jan-94 Sanofi-Aventis 216,439 -42.1 40.3infliximab Remicade May-92 Schering-Plough 209,188 37.8 42.9olanzapine Zyprexa Nov-96 Eli Lilly 206,132 -8.7 31.9etanercept Enbrel Mar-01 Amgen 193,285 28.5 45.4esomeprazole Nexium Aug-01 AstraZeneca 186,615 16.7 15.7rabeprazole sodium Pariet Jul-02 J & J 176,996 27.6 14.6venlafaxine Effexor XR Mar-98 Wyeth 169,754 -47.7 34.6epoetin alfa Eprex Mar-90 J & J 165,304 -4.2 13.6oxycodone hydrochloride Oxycontin Aug-96 Purdue Pharma 162,377 20.2 60.5lansoprazole Prevacid Jun-95 Abbott 160,319 10.0 25.0
12
First time generics launched latest 12 months
Molecule
NOC Date of
1st Generic Brand Name Brand Manufacturer Therapeutic Use
IMS (MAT) Brand Sales
$(000)'s Prior to Generic Launch
ceftriaxone September 20, 2006 Rocephin Hoffmann La Roche Antibiotic 29,041 tamsulosin October 3, 2006 Flomax Boehringer Ingelheim Prostate 59,155 venlafaxine October 6, 2006 Effexor XR Wyeth Anti-depressant 324,383 risperidone November 23, 2006 Risperdal Janssen-Ortho Anti-psychotic 107,936 pramipexole December 6, 2006 Mirapex Boehringer Ingelheim Anti-parkinson 26,399 ramipril December 12, 2006 Altace Sanofi-Aventis Blood Pressure 374,056 desmopressin January 22, 2007 DDAVP Ferring Anti-diuretic 13,514 perindopril February 1, 2007 Coversyl Servier Blood Pressure 50,844 cefprozil March 9, 2007 Cefzil Bristol Myers Squibb Antibiotic 28,309 fluticasone May 4, 2007 Flonase Glaxo SmithKline Anti-inflammatory 34,757 olanzapine June 6, 2007 Zyprexa Eli Lilly Anti-psychotic 224,846 ethinyl estradiol/levonorgestrel August 17, 2007 Alesse Wyeth Birth Control 53,593 gemcitabine August 23, 2007 Gemzar Lilly Cance 23,907 lisinopril/hydrochlorothiazide August 31, 2007 Zestoretic Astra Zeneca Blood Pressure 16,296 piperacillin sodium/tazobactam sodium September 24, 2007 Tazocin Wyeth Antibiotic 27,107 amoxicillin trihydrate/clavulanate potassium September 28, 2007 Clavulin-400 Glaxo SmithKline Antibiotic 1,398
13
Ranking of Retail Prescriptions by Corporation
Source:
2002 2003 2004 2005 2006MAT 00/07 Corporation Rx’s Market
(000’s) Share GrowthTotal Market 435,225 8.2
1 1 1 1 1 1 Apotex 82,856 19.0 14.82 2 2 2 2 2 Pfizer 34,284 7.9 7.73 3 3 3 3 3 Novopharm 33,386 7.7 14.2
12 9 7 5 5 4 Pharmascience 19,452 4.5 11.38 6 5 6 6 5 ratiopharm 18,766 4.3 8.26 4 4 4 4 6 J&J 18,719 4.3 -5.7
10 11 9 8 7 7 AstraZeneca 18,000 4.1 12.013 12 11 11 9 8 Genpharm 16,982 3.9 10.29 10 10 9 10 9 Abbott 16,872 3.9 10.04 5 8 10 11 10 Glaxo SmithKline 14,726 3.4 1.25 7 6 7 8 11 Wyeth 13,163 3.0 -17.2
11 13 13 12 12 12 Sanofi-Aventis 11,239 2.6 -20.215 14 14 14 13 13 Bristol-Myers Squibb 9,358 2.2 4.37 8 12 13 14 14 Merck Frosst 8,647 2.0 0.5
17 17 17 17 16 15 Bayer 8,211 1.9 21.4
12 months ending September 2007Rank
14
Canadian Generic Prescription Market12 months ending September 2007
Source:
$ (million) % % ChangeTOTAL GENERICS 3,697.2 16.4 GENERICS 3,426.8 92.7 16.3 AUTHORIZED GENERICS 270.4 7.3 18.8
Ranking of Drugstore & Hospital Sales by Generic Manufacturer
Source: 15
2002 Rank
2003 Rank
2004 Rank
2005 Rank
2006 Rank
MAT 09/07 Manufacturer
MAT 09/07 $(million)
Market Share Growth
Generic Market 3,697.2 100.0 16.41 1 1 1 1 1 Apotex Inc. 1229.1 33.2 14.62 3 2 2 2 2 Novopharm 634.1 17.2 30.54 4 4 3 4 3 ratiopharm 403.2 10.9 10.03 2 3 4 3 4 Genpharm 350.9 9.5 -3.75 5 5 5 5 5 Pharmascience 300.4 8.1 5.77 6 6 6 6 6 Sandoz 239.5 6.5 43.9
13 12 8 7 7 7 Cobalt Pharma 88.0 2.4 19.06 7 7 8 8 11 Hospira 73.2 2.0 10.2- - - - 10 8 Ranbaxy 60.2 1.6 206.19 9 9 9 9 9 Taro 39.2 1.1 5.5
18 15 11 10 11 10 Riva 34.5 0.9 31.510 10 10 11 12 12 Nu-Pharm 14.7 0.4 -1.112 13 12 12 13 13 Dominion Pharmacal 12.6 0.3 0.111 14 11 13 14 14 ProDoc 12.4 0.3 11.716 17 15 17 18 15 Europharm 10.5 0.3 45.7
16
Ranking of Retail Prescriptions by Generic Manufacturer
Source:
2002 Rank
2003 Rank
2004 Rank
2005 Rank
2006 Rank
MAT 09/07 Rank Manufacturer
MAT 09/07
Market Share Growth
Generic Market 207,091 100.0 15.01 1 1 1 1 1 Apotex Inc. 82,856 40.0 14.82 2 2 2 2 2 Novopharm 33,386 16.1 14.24 4 4 3 3 3 Pharmascience 19,452 9.4 11.33 3 3 4 4 4 ratiopharm 18,766 9.1 8.25 5 5 5 5 5 Genpharm 16,982 8.2 10.29 8 7 6 6 6 Sandoz 6,456 3.1 40.5
14 12 9 9 8 7 Riva 4,517 2.2 23.77 7 8 8 7 8 Taro 4,232 2.0 8.86 6 6 7 9 9 ProDoc 3,908 1.9 6.4
12 10 10 10 10 10 Europharm 3,154 1.5 39.021 20 15 13 11 11 Cobalt Pharma 2,658 1.3 57.4- - - - 12 12 Ranbaxy 2,342 1.1 141.2
11 13 16 15 15 13 Linson 1,448 0.7 55.310 11 12 11 13 14 Nu-Pharm 1,447 0.7 1.38 9 11 12 14 15 Valeant (I.C.N.) 1,252 0.6 8.1
17
Percent Share of Canadian Generic Prescription $ Market
85.9 87.990.8 91.5 93.1
14.1 12.19.2 8.5 6.9 7.3
92.7
0
20
40
60
80
100
2002 2003 2004 2005 2006 MAT09/07
Independent Generics Authorized Generics
Source: